Matinas BioPharma Holdings Inc. (AMEX: MTNB) is 15.44% higher on its value in year-to-date trading and has touched a low of $0.49 and a high of $2.22 in the current 52-week trading range. The MTNB stock was last observed hovering at around $1.57 in the last trading session, with the day’s loss setting it 0.0% off its average median price target of $3.75 for the next 12 months. It is also 68.6% off the consensus price target high of $5.00 offered by 6 analysts, but current levels are 47.67% higher than the price target low of $3.00 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Currently trading at $1.57, the stock is 34.57% and 57.70% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.23 million and changing 0.00% at the moment leaves the stock 87.26% off its SMA200. MTNB registered -4.27% loss for a year compared to 6-month gain of 123.11%. The firm has a 50-day simple moving average (SMA 50) of $1.0819 and a 200-day simple moving average (SMA200) of $0.8758.
The stock witnessed a 41.44% loss in the last 1 month and extending the period to 3 months gives it a 89.57%, and is 6.80% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 23.18% over the week and 12.70% over the month.
Matinas BioPharma Holdings Inc. (MTNB) has around 21 employees, a market worth around $338.48M and $0.10M in sales. Distance from 52-week low is 220.41% and -29.28% from its 52-week high.
Matinas BioPharma Holdings Inc. (MTNB) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Matinas BioPharma Holdings Inc. (MTNB) is a “Buy”. 6 analysts offering their recommendations for the stock have an average rating of 1.80, where 0 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Matinas BioPharma Holdings Inc. is expected to release its quarterly report on 05/18/2021 and quarterly earnings per share for the current quarter are estimated at -$0.03 with sales reaching $1.02M over the same period.The EPS is expected to grow by 17.50% this year, but quarterly earnings will post 933.30% year-over-year.
Matinas BioPharma Holdings Inc. (MTNB) Top Institutional Holders
68 institutions hold shares in Matinas BioPharma Holdings Inc. (MTNB), with 15.36M shares held by insiders accounting for 7.71% while institutional investors hold 25.60% of the company’s shares. The shares outstanding are 198.91M, and float is at 184.07M with Short Float at 8.92%. Institutions hold 23.63% of the Float.
The top institutional shareholder in the company is Boxer Capital, LLC with over 11.48 million shares valued at $8.79 million. The investor’s holdings represent 5.76% of the MTNB Shares outstanding. As of Sep 29, 2020, the second largest holder is Vivo Capital, LLC with 11.28 million shares valued at $8.64 million to account for 5.66% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 7.62 million shares representing 3.82% and valued at over $5.84 million, while Blackrock Inc. holds 1.12% of the shares totaling 2.24 million with a market value of $1.71 million.
Matinas BioPharma Holdings Inc. (MTNB) Insider Activity
A total of 3 insider transactions have happened at Matinas BioPharma Holdings Inc. (MTNB) in the last six months, with sales accounting for 0 and purchases happening 3 times. The most recent transaction is an insider purchase by STERN ADAM K, the company’s Director. SEC filings show that STERN ADAM K bought 20,000 shares of the company’s common stock on Aug 21 at a price of $0.83 per share for a total of $16600.0. Following the purchase, the insider now owns 3.3 million shares.
Matinas BioPharma Holdings Inc. (MTNB): Who are the competitors?
Omeros Corporation (OMER) is 18.25% up on the 1-year trading charts. Short interest in the company’s stock has fallen -0.55% from the last report on Nov 12, 2020 to stand at a total of 16.5 million short shares sold with a short interest ratio of 5.22.